Материал: Bovine Viral Diarrhea Virus Diagnosis, Management, and Control

in pregnant cattle, 107, 109

prevalence of infections with, 36–38, 46 principal reservoirs of, 223

progress in research on, 239–240 refocusing research on, 240–241 reproductive effects of, 223–224 respiratory disease, 10–11

respiratory disease, 2000-present, 21–22

risk factors for occurrence of infections, 49–52 skin biopsies and, 24

subclinical and clinical manifestation of, 108–109 taxonomy — defining characteristics of, 65–67 thrombocytopenia, 11

transient infection by, in combination with other pathogens, 54–55

true impact of, 241

type 2, emergence of, 3, 14

various outcomes of, depending on transmission and host, 225

Bovine viral diarrhea virus 1 (BVDV 1), 65, 209 differences between viruses from BVDV 2 and, 73 similarities between viruses from BVDV 2 and, 72–73 subgenotypes of, 210

transplacental infection with, 127 vaccine design and, 242

Bovine viral diarrhea virus 1a (BVDV 1a), 209 dendogram representing relatedness of nucleotide

sequences from BVDV 1b, BVDV 2 and, 211 Bovine viral diarrhea virus 1b (BVDV 1b), 209 Bovine viral diarrhea virus 2 (BVDV 2), xi, 65, 209

differences between viruses from BVDV 1 and, 73 incorporating strains of, in vaccines, 21, 25 misconceptions related to, 72

monoclonal antibodies and, 18

similarities between viruses from BVDV 1 and, 72–73 subgenotypes of, 211

transplacental infection with, 127 vaccine design and, 242 virulence factors and, 121, 123

Bovine viral diarrhea virus 2a (BVDV 2a), 211 Bovine viral diarrhea virus 2b (BVDV 2b), 211 Brachygnathism, 224

Bracken fern toxicity, 111

BRD. See Bovine respiratory disease Brinkhof, J., 19

Brock, K.V., 16, 18, 67, 68, 201, 214 Bronchopneumonia, colostrum source and, 54 Brownlie, J., 8, 9, 15

BRSV. See Bovine respiratory syncytial virus BT cells. See Bovine turbinate cells

Buffy coat cells, 198, 199 Buffy coat isolation, 204

Bulk milk testing, in Scandinavia, 21 Bulk tank milk

antibody levels in Sweden, 48 samples, 37

Bulls

acute and persistent infections in, 10

persistently infected, BVDV transmission and, 230 reducing BVDV transmission related to, 95 testicular infection and fertility of, 145–146

BVD. See Bovine viral diarrhea

BVD-MD. See Bovine viral diarrhea-mucosal disease BVDV. See Bovine viral diarrhea virus

BVDV genomic RNA, secondary structure of 5’ UTR/IRES of, 181

BVDV 1. See Bovine viral diarrhea virus 1 BVDV 1a. See Bovine viral diarrhea virus 1a BVDV 1b. See Bovine viral diarrhea virus 1b BVDV-specific nucleic acids, 25

BVDV 2. See Bovine viral diarrhea virus 2 BVDV 2a. See Bovine viral diarrhea virus 2a BVDV 2b. See Bovine viral diarrhea virus 2b

Calves

beef, from herd suffering from mucosal disease, 112 birth of, from persistently infected cow, 16 blindness in, 164

colon lesions in, from mucosal disease, 113 colostral immunity and vaccination of, 231–232 colostral protection and, 98 colostrum-deprived, BVDV in, 106 coronavirus infections in, 125

esophageal ulcers in, from mucosal disease, 112 histologic sections from ileum of both uninfected and

infected calves, 164

occurrence of other diseases and transient infection in, 54

postmortem image of palate of, from mucosal disease,

112

rota-virus infections in, 125

6-month-old seronegative, BVDV in, 106–107 thrombocytopenic, petechiation of ocular mucous

membranes in, 111 transient infection in, 59

Calving pens, environmental contamination of, 96 Camelidae family, serologic surveys of ruminant species

distributed within, 173 Camels, 116

Campylobacter spp., 210 Canada

BVDV type 2 emergence in, 14 mucosal disease in, 4

severe acute BVDV infection in cattle population in, 110 total annual costs in, 57

Caribou herds, seropositivity in, 173 Case-control studies, sampling in, 50 Caspase-mediated cellular destruction, 186 Cataracts, 107, 224

Catarrhal fever, 110

Cats (domestic), cell lines survey and, 173 Cattle. See also Persistently infected cattle

acute infections of, 121

BVDV transmission between sheep and, 231 cell lines survey and, 173

concurrent infection with BVDV and BRSV, 161

Cattle (continued)

pregnant, BVDV in, 107, 109 recovery in, 115

susceptible, sources of BVDV and mode of transmission to, 232

Cattle density, 52, 59, 197, 205

Cattle herds, risk factors for presence of PI animals in, 51 Cattle populations, circulation of BVDV in, 122

CD4+ T-lymphocytes, lymphoid tissue lesions and, 134 CD46 protein, 179

CD-87 isolate, 11 cDNA clone, 17, 18, 25 Cell death, 186–187

Cell lines, and support of growth of BVDV as possible indicators of host range, 173–174

Cell-mediated immune responses, to BVDV, 213, 214 Cell tropism, 174

Cellular enzymes, processing of envelope glycoproteins by, 183–184

Cellular immune response, 159, 242 Cellular remodeling, 188–189

Center for Veterinary Biologics (USDA), 210 Central nervous system

congenital defects of, 150

as immunological privileged site, 164 malformations in, 129

Cerebellar hypoplasia, 5, 107, 129, 150, 164, 224 Certified Semen Services, Inc., 146

Cervidae family, serologic surveys of ruminant species distributed within, 173

Cervids, persistent infections in, 172 Chase, C.C.L., 214

Cherry, B.R., 225

Chinese hamster ovary cells, 179 Chivers, W.H., 4, 131

Cho, H.J., 200

CHO cells. See Chinese hamster ovary cells Chronic mucosal disease, 113

Chu, J.J.H., 189

Classic swine fever virus, 5, 65, 173, 189, 198 BVDV replication and, 177

cellular factors and, 178 hosts and, 171

identification/differentiation of BVDV and, 203 Classification, molecular biology and, 65–74 Clinical BVDV infection, 110

Clinical features, 105–116

course of initial infection in immunocompetent cattle population, 105–107, 109

duration and severity of clinical signs, 115 occurrence in other ruminants, 115–116 recognition of, 109–115

bovine respiratory disease, 115 chronic mucosal disease, 113 clinical BVDV infection, 110 immunosuppression, 114–115 mucosal disease, 111–112 reproductive consequences, 113–114

severe acute BVDV infection, 110–111 subclinical infection, 109

venereal infections, 113 recovery from clinical signs, 115

Coefficient of infectiousness (â), 91, 92, 102 “Colitis cystica,” 134

Collett, M.S., 71

Colon lesions, in calves suffering from mucosal disease,

113

Colostral antibodies, 18

age of dairy calves and, 25

humoral immune response and, 158–159 prevention of transmission by, 98

role of, in acquiring BVDV, 106

Colostral immunity, vaccination of young calves and, 231–232

Colostrum

BVDV transmission via, 96

as mechanism of protection from BVDV, 213–214 Colostrum-deprived calves, BVDV in, 106 Colostrum management program, 98

Compendium of Veterinary Products, 210 Complement receptors (C3R), 157 Compton prototype virus, 217 Conception failure, 223, 224, 241 Conception rates, 55, 59

BVDV infection and, 148–149 ovarian dysfunction and, 127

Concurrent infections, 115 Confocal microscopy, 189 Congenital defects, 53, 55, 93, 241

of central nervous system, 150 types of, 114

Congenital infection, consequences of, 105 Congenital transmission

after 120–150 days in gestation, 94 persistent infection and, 94

Contact rate, 92 Contagiousness factors, 96 Control

by vaccination, 20–21, 25 without vaccination, 21

Control efforts, refocusing, 241–242 Control programs

for BVDV in beef cow herds, 234 for BVDV in dairy herds, 235

for BVDV in stocker/feedlot operations, 235 focus of, 209

to limit losses due to BVDV, 233–235 beef cattle, 233–234

dairy cattle, 234

stocker/feedlot operations, 234–235 vaccination to control BVDV-induced disease and

production losses, 231–233 Cooper strain, of BHV-1, 161 Copper deficiency, 110

Corapi, W.V., 9, 11, 12 Coria, M.F., 7, 10

Cornell University, College of Veterinary Medicine at, 3, 11

Coronavirus, 114 Cortese, V.S., 213, 215 Cows

occurrence of other diseases and transient infection in, 53–54

transient infection in, 48

Coxiella burnetii, 55, 57

cp BVDV (cytopathic BVDV), 12, 121, 123, 160, 197 , 240

cell death and, 186

cellular immune response and, 159

early and late onset mucosal disease and, 132, 133 intracellular signaling inhibition and, 188 lymphoid tissue lesions and, 134

molecular actions of, 22–23

pathogenesis of mucosal disease and, 131, 132 reproductive infections and, 151

spread of, in mucosal disease, 134 tissue lesions and, 133

vaccines and, 209, 210 CRIB cells, 178, 179

Cross-fence contact, inter-herd transmission and, 101 Cross-sectional studies, sampling in, 50

Crowding, BVDV transmission and, 96

Crypt epithelium, mucosal disease and infection of, 135 CSFV. See Classic swine fever virus

CSS. See Certified Semen Services, Inc.

C3 receptor expression, BVDV and reduction in, 158 C24V strain, 242

CTL. See Cytotoxic T-lymphocytes Curly haircoat, 150

CVB. See Center for Veterinary Biologics (USDA) Cytokines, 157, 158, 187

Cytopathic biotypes, 71, 72, 81 Cytopathic BVDV. See cp BVDV Cytopathic strains, discovery of, 4 Cytopathology, 83–84

Cytotoxic T-lymphocytes (CD8+), 159

Dairy calves, transmission of BVDV in, 98

Dairy cattle, control programs and management of, 234 Dairy herds, PCR assay for testing of, 20

Dairy operations, whole-herd testing by, 230 Dams

BVDV and clinical manifestations in, 113 identification of those carrying a PI fetus, 227–228

Danish Cattle Database, 52 DCs. See Dendritic cells

Dead calves, use of production records and laboratory evaluations of, 228–229

Decision tree analyses, 58 Deer, 105, 172, 173

Defective interfering (DI) particles, cytopathology and, 84

Delayed-onset mucosal disease. See Late-onset mucosal disease

Dendritic cells, 134, 157, 158 Deng, R., 67, 68

Dengue virus, 179 Denmark

cross-sectional study in, 51

economic evaluation of eradication program in, 58 economic losses in, before eradication campaign in, 57 eradication programs in, 21, 25, 239

incidence risk in, 48 persistently infected cattle in, 12 prevalence in, 52

Department of Agriculture, 5 Deranged osteogenesis, 150 Deregt, D., 18 Dexamethasone, 10

DFA. See Direct fluorescent antibody Diabetes mellitus, in PI animals, 129 Diagnosis, 197–205

antibody detection, 199–200 virus neutralization test, 200

direct antigen detection, 198–199 enzyme-linked immunosorbent assay, 199 immunofluorescence, 198

immunohistochemistry of peripheral blood leukocytes, 198

immunohistochemistry of skin biopsies, 198–199 enzyme-linked immunosorbent assay, 200–201 immunoperoxidase and immunofluorescence, 201 milk as a diagnostic sample, 203

1946-1969, 4–6 1970s, 7–8 1980s, 12

reverse transcription-polymerase chain reaction, 201–203

nested PCR, 202

strain differentiation, 202–203 TaqMan, 202

screening for persistently infected animals, 203–204 skin biopsies and, 24

virus isolation and, 18, 199–200 Diagnostic tests

of clinically ill animals with BVDV infection, 229 for detection of PI animals, 226–227

virus isolation, 226

results, of clinically ill animals with BVDV infection,

229

Diagnostic tests for detection of PI animals for identifying PI calves, 227 immunohistochemistry, 226

polymerase chain reaction, 226–227 serology, 227

DI particles. See Defective interfering (DI) particles Direct antigen detection, 198–199

immunofluorescence, 198

immunohistochemistry of peripheral blood leukocytes, 198

immunohistochemistry of skin biopsies, 198–199 enzyme-linked immunosorbent assay, 199

250

Direct economic cost, 56 Direct fluorescent antibody, 198 Direct RT-PCR, 202

Disease form, vaccine protection based on, 213 Disease surveillance, 241–242

DNA, 25

Domes, loss of, 134

Domestic animals, BVDV transmission and, 231 Done, J.T., 8

Donis, R.O., 22, 178

Double fencing, minimizing BVDV transmission and, 101

Double-stranded replicative form, of RNA, 83 dPCR. See Direct RT-PCR

Drew, T.W., 20, 202, 203 dsRNA, 188

Dual genotype natural infections, 100 Dual persistent infections, 150 Dubovi, E.J., 18

Duffel, S.J., 214 “Dummy calves,” 150

Duration of infectiousness, 91, 92, 101, 102 Dysmyelogenesis, 129

E. coli, 110, 114, 201 Eagle’s MEM, 204 Earlier values, 56

Early mucosal disease, 132–133

Ear notch immunohistochemistry, 212 Ear notch samples, 198, 204

EBTr. See Embryonic trachea cell line

Economic analyses, functions in performance of, 56 Economic impact of BVDV, 56–58, 59

economic evaluation

of control strategies at herd level, 58 of national eradication programs, 58

at herd level, 57

losses in larger populations and at national level, 57–58

optimizing decisions based on economic calculations, 58

Economic losses, 145, 177, 197

ED cell system. See Equine dermal cell system Edwards, S., 12

Electron beam irradiation, pestivirus virion and, 66 ELISA. See Enzyme-linked immunosorbent assay Elk, 105, 172

Ellis, J., 215

Embryonic trachea cell line, 199 Embryo transfer

BVDV transmission and, 95, 231 inter-herd transmission and, 101

Endemic state, 92 END method, 23 Endsley, J.J., 214 Envelope glycoproteins

processing of, by cellular enzymes, 183–184 virus binding and, 82

Index

Environment

BVDV transmission and, 95–96 outcome of reproductive disease and, 151

Environmental stress, 105

Enzyme-linked immunosorbent assay, 19, 37, 197, 198–199, 200–201, 202, 226

skin biopsies and, 24

testicular infection testing and, 146 EO protein, 71

Epidemiological studies for estimation

of herd level prevalence based on screening samples/bulk milk samples, 45

of incidence, 47–49

of prevalence of animals with antibodies against BVDV, 39–42

of prevalence of virus positive and persistently infected animals, 43–44

on occurrence of different genotypes, 46 Epithelial surfaces, BVDV and damage to, 110 Equine dermal cell system, 199

Eradication programs, 25–26

national, economic evaluation of, 58 in Scandinavia, 46

virus isolation, seroconversion and, 172 Esophageal ulcers, mucosal disease and postmortem

image of, 112

Estonia, persistently infected animals in, 46 Ethylenimine, pestivirus virion and, 66 Etiology, 49

E2 (envelope glycoprotein) region, 209

E2 monoclonal antibodies, 12

E2 protein, 68, 71, 82

E2-specific monoclonal antibodies, 18 Europe

formal monitoring of wildlife in, 171 prevalence in, 46

European Osloss strain, 11, 12 EV. See Earlier values

Exchange rate between currencies, 56 Exocytosis, virion assembly and, 85

Experimental BVDV infection, disease syndromes in non-bovine hosts due to, 172

Face flies, BVDV transmission and, 96 Failure to thrive, 241

FAT. See Fluorescent antibody technique FBS. See Fetal bovine serum

FcR, 157, 158

FCS. See Fetal calf serum

FDCs. See Follicular dendritic cells

Feed bunk space, minimizing BVDV transmission and, 101 Feedlot cattle

respiratory disease in, 21–22 vaccines for, 6

Feedlot operations

control programs and management of, 234–235 intra-herd transmission and, 100

Feedlots, “shipping fever” pneumonia and, 10 Fence breakout, risk factors and, 51, 59 Fence-line contact, managing, 233

Fertility, reduced, 113 Fetal abnormalities, 107

Fetal bovine serum, 5, 7, 8, 197 Fetal calf serum, 95

Fetal death, 157

Fetal fluid collection, 228 Fetal infection, 114, 128–130

abortions and, 128–129 incidence risk of, 48

during middle trimester, 150

noncytopathic BVDV and, 23, 24 persistent infections and, 129 preventing, 152

teratogenic effects of, 129–130

vaccines and protection against, 25, 217–219 Fetal protection

against BVDV, 21 vaccines and, 232–233

Fetus, BVDV transmission to, 93 Ficoll-Paque/Macrodex, 204 Finland

cattle density in, 52

eradication programs in, 21, 239 prevalence in, 46

5 UTR (5 untranslated region), 66, 81, 182, 202, 209 degree of sequence identity between pestiviruses in,

66

virus replication and, 71, 82 Flativirus family, 65

Flaviviridae, 12, 187 genomes, 82

Flavivirus IRES, translation initiation from, 183 Flies, BVDV transmission and, 96

Flores, E.F., 15, 178 Flow cytometry, 19

Fluorescent antibody technique, 6, 8 Fluorescent probes, 20

Folding of proteins, 184 Follicular dendritic cells, 134 Fomites

acute infection and, 94

BVDV transmission and, 95–96, 231 Foot and mouth disease, 110

Formulas

herd sensitivity/herd specificity, 37 incidence of BVDV infection, 92 incidence risk over animal’s life, 49 true prevalence, 36

vaccination protection, 92 Fox, Francis, 3, 4

F-P/M. See Ficoll-Paque/Macrodex Fray, M.D., 16

Freisen bulls, 10 Fritzemeier, J., 16

Fuller, D.A., 6

Fulton, R.W., 22, 203

Gait disorders, 164

Gamma irradiation, pestivirus virion and, 66 Gastroenteritis virus, synergism between BVDV and, 161 Gastrointestinal parasites, 110

Genetic recombination in BVDV, 83

spontaneous and postvaccinal disease and, 15 Genomic diversity, 239

Genotypes, 209, 239 BVDV, 71–73, 160

occurrence of, and epidemiological studies, 46 Genotyping, 71

German roe deer, 172 Germany

BVDV genotypes identified in, 46 eradication programs in, 25 prevalence in, 52

Gestational age of fetus, 105

Gestational vertical transmission, management and control of BVDV and, 223

Gestation stage

consequences of BVDV infection

from 30–125 days of gestation, 149–150 from 125–175 days of gestation, 150 from 175 days of gestation to term, 150

prior to implantation (30–45 days), 147–149 effect of, at time of BVDV infection of susceptible

pregnant cows, 224

impact of, on outcome of reproductive disease, 147–150

Gilbert, S.A., 203 Gillespie, J.H., 3, 131

Giraffe, viruses isolated from, 66 Givens, M.D., 201

Gnotobiotic calves, 158

Gnotobiotic lambs, severe respiratory disease in, 161 Goats, 116, 172

cell lines survey and, 173 congenital infection in, 174

gp48, 71

Graham, D.A., 54, 201

Granulocyte-macrophage colony-stimulating factor, 158 Great Britain, economic losses in, 57

Grooms, D.L., 24, 107, 229 Growth retardation, 150, 224 Gruber, A.D., 202 Grummer, B., 189 Gutekunst, D.E., 6

Haematopota pluvialis, 96

Haines, D.M., 19, 22

Hamel, A.L., 202

Hannover Veterinary School, 3

Harpin, S., 19

HCV. See Hepatitis C virus; Hog cholera virus